What Ureaderm Lactato Treats: Main Uses and Benefits

The primary therapeutic domain for Ureaderm Lactato involves the symptomatic management of conditions characterized by dryness and skin thickness, consistent with the properties of its active ingredients. This preparation is commonly used in clinical settings to address conditions characterized by severe, persistent dryness (Xerosis), hyperkeratosis, and certain forms of Ichthyosis.

Intensive Relief for Pathological Skin Dryness and Scaling

Ureaderm Lactato helps manage the associated symptomatic discomfort of Xerosis and hyperkeratosis, including manifestations of itching, skin tightness, roughness, and excessive scaling or flaking. It is relevant for addressing symptoms that create noticeable physiological strain and are observed alongside chronic skin disorders such as Atopic Dermatitis and Psoriasis, where it is often used as adjuvant care.

It contributes to easing the overall symptom load and supports general well-being during symptomatic phases, contributing to improved comfort and supporting the skin's pliability.

Quick Fact: Relief for Rough and Thickened Skin

Regulatory References

1. NIH MedlinePlus overview of topical Ammonium Lactate

Who Can and Cannot Use Ureaderm Lactato?

Official regulatory documents define the strict eligibility criteria for Ureaderm Lactato, focusing on patient characteristics and application conditions.

Populations Allowed The formulation is officially documented for use across all major age groups, including the paediatric population, adults, and older people, under standard labeled conditions.

Absolute Contraindication The medicine is strictly contraindicated for any individual with a known hypersensitivity or allergy to the active substances (Urea and Lactic Acid) or to any of the product's excipients.

Restricted or Conditional Use Use of Ureaderm Lactato is subject to several specific limitations:

• Application Site: The product must not be applied to raw areas, fissures, inflamed skin, or open wounds. Contact with the eyes and mucous membranes must be avoided.
• Systemic Health: Extensive use is not advised without medical supervision for subjects diagnosed with severe renal impairment due to the potential for systemic absorption of urea.
• Life Stages: For pregnant women, use is advised with caution due to the absence of specific data. Breast-feeding women must follow the specific instruction to remove the product from the breast area before feeding.

Interactions with other medicines and products

Official regulatory information regarding Ureaderm Lactato focuses on its potential to influence the effects of other substances when applied to the skin.

Pharmacodynamic and Penetration Effects

Urea, an active component, is documented to act as a penetration enhancer. This effect may increase the release of active substances from other topical preparations and enhance their penetration into the skin. This pharmacodynamic effect is a primary consideration when co-administering with certain topical medications.

Specific Interacting Substances

The penetration-enhancing effect is specifically noted in regulatory documentation for co-administration with the following classes of active substances:

• Corticosteroids: Increased skin absorption and effect.
• Dithranol: Increased skin absorption and effect.
• Fluorouracil: Increased skin absorption and effect.

General and Population-Specific Considerations

There is an explicit regulatory note concerning the risk of systemic absorption. Because of the potential for transcutaneous penetration of urea into the body, the extensive use of this product on large areas should be considered with caution in individuals with severe renal impairment. Additionally, the final formulation of the cream may have a low pH, which carries a theoretical possibility of affecting the stability of certain other co-applied drug molecules.

Urea, a low molecular weight organic compound, operates as a keratolytic agent at elevated concentrations. This mechanism promotes the disaggregation of the cornified layer by solubilizing the intercellular cement. Concurrently, Urea disrupts the hydrogen and ionic bonds within the keratin matrix. Lactate, acting as an alpha-hydroxy acid (AHA), modulates the keratinization process by promoting the physiological shedding of corneocytes. As a direct consequence of both actions, the stratum corneum thickness and density are structurally modified. In addition, Urea functions as a compound that increases the water-binding capacity of the stratum corneum via hygroscopic action, facilitating the drawing of water into the outermost epidermal layer. This physiochemical action is associated with influencing the structural organization of stratum corneum lipids, which can modify the hydrogen bonding network within the cornified envelope, thereby modulating trans-epidermal water loss.

Guidelines for using the topical preparation containing Urea and Lactic Acid, such as Ureaderm Lactato, follow specific administration protocols. The established route of administration is exclusively topical, intended only for application to the skin. The medication is typically manufactured as a lotion or cream, defining the appropriate physical application technique.

The standardized dosing frequency is twice daily. This schedule is designed to support the continuous, long-term maintenance required for chronic conditions such as ichthyosis or severe xerosis.

Procedurally, administration requires specific steps to ensure correct use. If the formulation is a lotion or emulsion, the container must be shaken well before each application. A thin layer of the preparation is then applied to the affected areas and must be rubbed in thoroughly. Usage constraints stipulate that contact must be strictly avoided with the eyes, lips, and other mucous membranes. Furthermore, the safety and effectiveness of the 12% Ammonium Lactate formulation, a common strength in this category, have been established for use in infants and children. In the event that an application is missed, instructions advise skipping the dose entirely if it is near the next scheduled time.

Research evidence / Overview of Studies for Ureaderm Lactato

Evidence for Use in Severe Dry Skin (Xerosis) and Roughness

The evidence base for topical preparations containing Urea and Lactic Acid was studied for conditions characterized by severe dry skin (known as Xerosis) and roughness. Research primarily consists of Randomized Controlled Trials (RCTs), where the preparation was compared with an inactive vehicle (placebo) or a basic moisturizer. These studies monitored objective parameters, including changes in skin hydration (measured using specialized instruments) and Transepidermal Water Loss (TEWL), which is an indicator of the skin's barrier function.

Clinical assessments in various trials described changes in visible signs of dryness and clinician-rated roughness compared to vehicle-only controls. What remains uncertain is the long-term maintenance of these observed patterns. Follow-up durations were limited, meaning the sustained effects of application beyond a few months are not fully established. Comparative evidence is also lacking regarding how this specific combination preparation performs against non-urea-based prescription emollients.

Evidence for Keratolytic Uses in Scaling Disorders

The combination product was evaluated in research contexts involving conditions marked by excessive scaling and skin thickness, such as Ichthyosis Vulgaris and Keratosis Pilaris. The study designs used included controlled clinical studies and Split-Body Trials, where different treatments were observed in separate areas of the same patient. Studies monitored clinical outcomes related to physical discomfort, primarily assessing changes in metrics for scaling, flakiness, and overall skin texture and smoothness.

Research highlights changes measured during the study period, particularly within the 4-to-12-week observation windows, related to these scaling symptoms. Research limitations include that sample sizes were modest in some clinical studies, which may limit how broadly the findings apply to all patients with these disorders. Furthermore, existing studies have provided limited insight into long-term outcomes for sustained control of these conditions.

Research on Adjuvant Care for Chronic Dermatoses

The preparation was studied for its role as supportive or adjuvant care in conditions characterized by fluctuating or episodic manifestations like Atopic Dermatitis and Psoriasis. This evidence is often derived from Systematic Reviews and controlled studies where the product was observed in patients with these specific conditions. Studies explored outcomes related to skin barrier function metrics and patient-reported outcomes describing perceived discomfort such as pruritus (itching) and scaling.

Findings indicate patterns where the inclusion of the preparation in a supportive regimen was associated with changes in these monitored outcomes. The evidence for this use is limited by the fact that the preparation is usually studied as an addition to standard therapy, and the specific independent role in long-term disease relapse rates is not fully established.

Key Studies & References

1. Systematic review and meta-analysis of the effectiveness of urea-based moisturizer on dry skin in diabetes melitus patients
2. Ammonium Lactate Topical: MedlinePlus Drug Information (used for core indications and classification)

Common questions about Ureaderm Lactato (FAQ)

Q: Is Ureaderm Lactato sold over the counter, or is it prescription-only?

A: According to the official product information, topical formulations similar to this are classified in the United States as Over-The-Counter (OTC) drugs. This means that in these regions, the product can be purchased without a prescription.

Q: Can Ureaderm Lactato be used year-round, or is it better for certain seasons?

A: Official information supports the use of the product for the long-term maintenance of chronic skin conditions. However, the label includes a specific precaution regarding minimizing or avoiding sun exposure on treated skin, which is often a key consideration across seasons or for specific outdoor activities.

Q: Are there any known issues with Ureaderm Lactato and sun exposure?

A: Regulatory documents include a statement regarding minimizing or avoiding exposure to both natural and artificial sunlight on treated areas. The label also notes that protective clothing may be considered if sun exposure is unavoidable.

Q: What happens if a small amount of Ureaderm Lactato is accidentally swallowed?

A: The medication is intended for external use only and is not to be swallowed. Regulatory labels state that contact with a Poison Control Center or local emergency services is advised in the event of accidental ingestion or suspected overdose.

Q: Is Ureaderm Lactato available in different strengths or formulations?

A: Products in this category are commonly available in different forms, such as a cream or a lotion. The active ingredients are also formulated in various concentrations, such as 12% Ammonium Lactate.

Q: Is Ureaderm Lactato considered a high-potency skin treatment?

A: Official regulatory documents classify this product as a Topical Emollient and a Keratolytic Agent. The term 'high-potency' is typically a specific classification reserved for other categories of dermatological medications, such as certain topical corticosteroids, which is a class separate from this product.

Q: What are the inactive ingredients in Ureaderm Lactato?

A: The regulatory label explicitly lists all inactive ingredients, also known as excipients, for a specific formulation. These may include ingredients such as Cetyl Alcohol, Glycerin, Propylene Glycol, Stearic Acid, and Parabens. The precise inactive ingredients can vary depending on the product’s manufacturer and specific formulation.

Q: What are the ingredients that someone with eczema should watch out for in Ureaderm Lactato?

A: The product is officially contraindicated if a person has a known hypersensitivity to any of the ingredients listed on the label. Official documents provide the complete list of excipients, which allows individuals to compare the product contents against any known sensitivities.

Q: How quickly should I expect to see an effect from Ureaderm Lactato?

A: Studies that examined the effectiveness of the product monitored changes in skin conditions over structured timeframes. Clinical improvement was typically measured during observation windows ranging from 4 to 12 weeks of continuous use.

Q: Do experts recommend Ureaderm Lactato for dry skin on the feet?

A: The product’s primary official indications include the treatment of xerosis (severe dry skin) and ichthyosis vulgaris. While regulatory documents do not list specific body parts, the treatment is indicated for conditions such as xerosis (severe dry skin) and ichthyosis vulgaris.

Q: Can Ureaderm Lactato interact with other skincare products like retinol or AHAs?

A: Regulatory documentation describes one of the active components, Urea, as a penetration enhancer. This means the product has the potential to increase the release and absorption of active substances from other topical preparations that are applied to the same area of skin.

Q: Is Ureaderm Lactato generally considered appropriate for sensitive skin types?

A: Official safety information notes that transient stinging or burning are common adverse effects that may occur upon application, particularly if the skin is compromised. Regulatory information also describes the need for caution when the product is applied to the face due to the potential for irritation.

Q: Can applying Ureaderm Lactato too often cause any issues?

A: The product's regulatory labeling indicates a specific application frequency and includes a caution against using the medication more often than directed. Exceeding the recommended use may increase the likelihood or severity of common local adverse reactions, such as stinging, burning, or irritation.

Q: What should be done if Ureaderm Lactato gets into the eyes?

A: Official instructions state that contact with the eyes must be avoided. Regulatory labeling indicates that if accidental contact occurs, the affected area should be rinsed with cool tap water.

Q: How long does the moisturizing effect of Ureaderm Lactato typically last?

A: The regulatory dosing schedule is set at twice daily to support the continuous, long-term maintenance required for chronic skin conditions. The frequency of application helps maintain the therapeutic effect throughout the day.

Q: Does Ureaderm Lactato need to be absorbed completely before putting on clothes?

A: Official administration instructions describe applying the product in a thin layer and rubbing it in thoroughly to the affected areas. This process aims to ensure the product is fully incorporated into the skin during application.

Q: Why is Ureaderm Lactato not recommended for use on broken or severely irritated skin?

A: Regulatory safety information explains that the common adverse effects, such as stinging or burning, are more likely to occur when the product is applied to skin with fissures, erosions, or abrasions (forms of broken or compromised skin).

Q: Is Ureaderm Lactato a steroid or does it contain any steroids?

A: The product is officially classified as a Topical Emollient and a Keratolytic Agent. Its active ingredients are Urea and Lactic Acid. Official documents do not list steroids as components; instead, they note that the product may interact with external corticosteroids when co-applied, confirming it belongs to a separate medication class.

Q: What is the difference between an emollient and a humectant, and which is Ureaderm Lactato?

A: The product is classified as a combination of a Topical Emollient and a Keratolytic Agent. Its active ingredient, Urea, functions as a humectant—a substance that helps draw water into the skin. As a whole product, it is used to moisturize (emollient) and smooth (keratolytic).

Q: Do any official documents describe Ureaderm Lactato being used for heel fissures?

A: Regulatory documents contain a precaution that application to skin with fissures (a form of skin cracking) may cause a transient stinging or burning sensation. The product is restricted from use on open wounds or severely inflamed skin.

How to Store and Dispose of Ureaderm Lactato

Storage and disposal must strictly adhere to the requirements documented in official regulatory labeling for Urea and Lactic Acid topical preparations to maintain product stability and ensure safety.

Storage Conditions

Ureaderm Lactato must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing and should not be exposed to excessive heat or moisture. The container must be kept tightly closed when not in use.

Safety and Disposal

For household safety, the medicine must be kept out of the reach and sight of children. Unused or expired medication must be properly discarded according to local requirements for pharmaceutical waste and must not be flushed down a toilet or poured down a drain.